ClinicalTrials.gg
CompletedNCT02870309Updated Oct 28, 2021Results posted

Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency

A Phase 1/2 interventional study of Alpha-1 MP in Alpha1-Antitrypsin Deficiency, sponsored by Grifols Therapeutics LLC. Completed at 2 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-10-28.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.

Enrollment
21st of 25
4 · median 30
Started
2016
with 4 others
Phase 1/2
4 of 25
none open now
Registered
19th of 25
by date
Lead sponsor
10 of 25
Grifols Therapeutics LLC

Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 21st largest by enrollment, is one of 5 that started in 2016, is one of 4 in phase 1/2, and was the 19th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About alpha 1-Antitrypsin

alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, or all of them as a file.
02

Study summary

This study is a multicenter, open-label trial to evaluate the safety and pharmacokinetics of weekly intravenous infusions of 60 mg/kg of Alpha-1 MP (alpha1-proteinase inhibitor (human), modified process) for 8 weeks.

Read the detailed description

This study is a multicenter, open-label trial to evaluate the safety and pharmacokinetics of weekly intravenous (IV) infusions of 60 mg/kg of the investigational drug in participants with alpha1-antitrypsin deficiency (AATD). The trial will be conducted at approximately 5 medical institutions in Japan, aiming to enroll a minimum of 3 adult participants or more. The trial will consist of a screening period scheduled within 3 weeks before trial entry, an open-label treatment period for 8 weeks, and a pharmacokinetic (PK) evaluation period for 1 week. At the Week 9 visit when the PK evaluation period is completed, participant will be asked whether they would like to participate in an extension trial (GTI1401-OLE). For participants not intending to participate in the extension trial, the date of follow-up/study completion visit (30 days [4 weeks] after the last dose of the investigational drug) will be arranged. Participants will participate in this trial for approximately 14 weeks from the start of the screening period through the completion of the trial.

At the screening visit (scheduled within 3 weeks before trial entry), after providing informed consent (agreement based on adequate explanation and understanding of the treatment plan), participants will be evaluated for eligibility for participation during the screening period. Participants considered eligible will enter the 8-week treatment period to receive a total of 8 weekly IV infusions of 60 mg/kg of Alpha-1 MP. The initial IV infusion will be given at the Week 1 (baseline) visit. During the treatment period, participants will receive weekly IV infusions of Alpha-1 MP at the Weeks 1 (baseline), 2, 3, 4, 5, 6, 7, and 8 visits. After the last IV infusion of Alpha-1 MP at the Week 8 visit, participants will enter the 1-week PK evaluation period. During this PK evaluation period, participants will visit the study center to undergo blood sampling for PK evaluation at the PK1 visit (the next day of the Week 8 visit), the PK2 visit (2 days after the Week 8 visit), the PK5 visit (5 days after the Week 8 visit), and at the Week 9 visit. At 30 days after the last dose (Week 8), participants will visit the study center for follow-up/study completion (Week 12). All participants will undergo blood sampling for the measurement of alpha1-PI trough concentrations at the Weeks 1 (baseline), 7, and 8 visits (blood samples will be collected before dosing) as well as at the Week 9 visit.

Blood samples for the evaluation of PK parameters will be collected from Week 8 to Week 9. The blood sample collected before the infusion of Alpha-1 MP at the Week 8 visit and the blood sample for PK evaluation collected at the Week 9 visit (7 days after the infusion at the Week 8 visit) will be also used for the measurement of alpha1-PI trough concentrations for Weeks 8 and 9.

At the Week 9 visit, participants will be asked whether they would like to participate in the extension trial (GTI1401-OLE). Participants intending to participate in the extension trial will be able to continue the treatment with IV infusions of 60 mg/kg of Alpha-1 MP for at least another year (participants will be further asked whether they would like to continue the treatment at yearly intervals) for the purpose of evaluation of the safety of long-term Alpha-1 MP treatment. Participants not intending to enter the extension trial will visit the study center for follow-up/study completion at 30 days (4 weeks) after the last dose of Alpha-1 MP (Week 12).

03

Conditions studied

  • Alpha1-Antitrypsin Deficiency
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged ≥20 years at the time of providing .
  • Participants with clinically apparent pulmonary emphysema diagnosed by Computed Tomography (CT) scan.
  • AATD participants with documented serum alpha1-PI levels of \<50 mg/dL (i.e., 11 µM) as measured by nephelometry. In participants with no previously documented serum alpha1-PI levels, their serum alpha1-PI levels measured by nephelometry during the screening period must be \<50 mg/dL.
  • Participants whose percentage of forced expired volume in 1 second/forced vital capacity /forced vital capacity (FEV1/FVC) after inhalation of a bronchodilator is \<70% during the screening period [equivalent to the criterion for the diagnosis of (COPD)].
  • Participants who are willing to and able to provide signed written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Participants with moderately or severely deteriorated lung function in the 4 weeks before the Week 1 (baseline) visit.
  • Participants whose percentage of forced expired volume in 1 second/forced vital capacity (% after inhalation of a bronchodilator is \<30% during the screening period.
  • Participants who have undergone lung transplantation or liver transplantation.
  • Participants who have undergone any lung surgery (excluding lung ) in the past 2 years.
  • Participants with increased liver enzymes , alanine aminotransferase and alkaline phosphatase (AST, ALT, and ALP) ≥2.5 times the .
  • Participants with severe complications including but not limited to congestive heart failure and liver cirrhosis.
  • Participants who have developed any malignant tumor (including malignant melanoma; however, other forms of skin cancer are excluded) in the past 5 years.
  • Pregnant women, breastfeeding women, or women of who do not intend to use effective methods (use of oral, injection, or implant hormonal contraceptives; placement of an intrauterine device (IUD) or intrauterine contraceptive system; concomitant use of spermatocidal foam, gel, film, cream, suppository and condoms or cervical caps; male sterilization; or abstinence) throughout the trial period or male participants who have a partner who is of childbearing potential and is unwilling to use effective contraceptive methods throughout the trial period.
  • Participants with a past history of hepatitis A virus, virus, virus, or (HAV, HBV, HCV, or HIV) infection, or participants currently presenting with clinical signs or symptoms suggestive of such infection.
  • Participants with a smoking history in the past 6 months, or participants tested positive for urinary cotinine levels at the screening visit.
  • Participants participating in another clinical trial within 4 weeks before the Week 1 (baseline) visit.
  • Participants with a history of anaphylactic or severe systemic reactions to any plasma derived alpha1-PI product or other blood products.
  • Participants who have continuously received any systemic therapy at a prednisone-equivalent dose >5 mg/day within 4 weeks before the Week 1 (baseline) visit (Note: inhaled steroids are not regarded as systemic steroids).
  • Participants who have used any systemic or aerosolized antibiotic drug for the treatment of exacerbation within 4 weeks before the Week 1(baseline) visit.
  • Participants with a previous or current diagnosis of selective, severe Immunoglobulin A (IgA) deficiency.
  • Participants who are mentally challenged and cannot independently give consent.
  • Participants who have difficulty in adhering to the protocol or its procedures in the opinion of the investigator.
  • Participants who have medical conditions that may confound the results of this clinical trial or may endanger other participants during the participation in this clinical trial in the opinion of the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Alpha-1 MP

    Participants received 8 IV infusions of 60 mg/kg Alpha-1 MP administered weekly at an infusion rate not exceeding 0.08 mL/kg/min over approximately 15 minutes, up to Week 8.

    Biological: Alpha-1 MP

Interventions

  • BiologicalAlpha-1 MP

    Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as α1-antitrypsin

    Also known as: Prolastin-C

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether considered related to the medicinal product. TEAEs were defined as any AE occurring after or on the first Alpha-1 MP infusion until the final visit of study.

    Time frame: Up to Week 12

  2. Number of Participants With Adverse Drug Reaction (ADRs)

    ADRs were defined as adverse events (AEs) which were in the investigator's opinion of causal relationship to the study treatment. AE was defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product.

    Time frame: Up to Week 12

  3. Number of Participants With Serious Adverse Events (SAEs)

    A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Up to Week 12

  4. Number of Discontinuations Due to Adverse Events (AEs) or Serious Adverse Events (SAEs)

    An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether considered related to the medicinal product. TEAEs were defined as any AE occurring after or on the first Alpha-1 MP infusion until the final visit of study. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Up to Week 12

  5. Number of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

    COPD exacerbation was defined as an increase in respiratory symptoms (dyspnea, increased cough, and/or production of sputum) over baseline that usually requires medical intervention.

    Time frame: Up to Week 12

Secondary outcomes

  1. Trough Level of Total alpha1-PI for Weekly IV Infusions of 60 mg/kg Alpha-1 MP

    Time frame: Baseline (Week 1), Weeks 7, 8 (prior to the start of infusions of Alpha-1 MP) and Week 9 (168 hours post infusion)

07

Results

Posted Feb 18, 2021

Participant flow

The trial was conducted at 2 medical institutions in Japan from 29 July 2016 to 15 March 2017.

Participant flow — Overall Study
MilestoneAlpha-1 MP
Started4
Completed4
Not completed0

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether considered related to the medicinal product. TEAEs were defined as any AE occurring after or on the first Alpha-1 MP infusion until the final visit of study.

Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsAlpha-1 MP
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)3
PrimaryNumber of Participants With Adverse Drug Reaction (ADRs)

ADRs were defined as adverse events (AEs) which were in the investigator's opinion of causal relationship to the study treatment. AE was defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product.

Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Adverse Drug Reaction (ADRs)
ParticipantsAlpha-1 MP
Number of Participants With Adverse Drug Reaction (ADRs)1
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsAlpha-1 MP
Number of Participants With Serious Adverse Events (SAEs)0
PrimaryNumber of Discontinuations Due to Adverse Events (AEs) or Serious Adverse Events (SAEs)

An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether considered related to the medicinal product. TEAEs were defined as any AE occurring after or on the first Alpha-1 MP infusion until the final visit of study. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Number of Discontinuations Due to Adverse Events (AEs) or Serious Adverse Events (SAEs)
ParticipantsAlpha-1 MP
Number of Discontinuations Due to Adverse Events (AEs) or Serious Adverse Events (SAEs)0
PrimaryNumber of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

COPD exacerbation was defined as an increase in respiratory symptoms (dyspnea, increased cough, and/or production of sputum) over baseline that usually requires medical intervention.

Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
ParticipantsAlpha-1 MP
Number of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations0
SecondaryTrough Level of Total alpha1-PI for Weekly IV Infusions of 60 mg/kg Alpha-1 MP
Time frame:
Baseline (Week 1), Weeks 7, 8 (prior to the start of infusions of Alpha-1 MP) and Week 9 (168 hours post infusion)
Reported as:
Mean · milligram/decilitre
Trough Level of Total alpha1-PI for Weekly IV Infusions of 60 mg/kg Alpha-1 MP
milligram/decilitreAlpha-1 MP
Week 111.450 ± 3.5162
Week 755.567 ± 7.2231
Week 855.425 ± 7.2325
Week 956.900 ± 12.9378

Adverse events

Collected over From the time of informed consent through the end of study (Up to Week 12).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alpha-1 MP0/4 (0%)0/4 (0%)3/4 (75%)
Most frequent other events
Most frequent other events
EventAlpha-1 MP
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders2/4
FatigueGeneral disorders1/4
Hepatic function abnormalHepatobiliary disorders1/4
Viral upper respiratory tract infectionInfections and infestations1/4
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/4

Baseline characteristics

Safety population included all the participants who received any amount of Alpha-1 MP.

Age, Continuous
Age, Continuous(years)Alpha-1 MP
Mean60.8 ± 5.56
Sex: Female, Male
Sex: Female, Male(Participants)Alpha-1 MP
Female1
Male3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Alpha-1 MP
American Indian or Alaska Native0
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

2 sites
  • Hokkaido University Hospital
    Sapporo, 060-8648, Japan
  • Juntendo University Hospital
    Tokyo, 113-8431, Japan
09

References and documents

Publications

  • Seyama K, Nukiwa T, Sato T, Suzuki M, Konno S, Takahashi K, Nishimura M, Steinmann K, Sorrells S, Chen J, Hayashi KI. Safety and pharmacokinetics of Alpha-1 MP (Prolastin(R)-C) in Japanese patients with alpha1-antitrypsin (AAT) deficiency. Respir Investig. 2019 Jan;57(1):89-96. doi: 10.1016/j.resinv.2018.09.006. Epub 2018 Nov 8. PubMed 30416054 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Mar 2017, 7 months.

Results were first posted in Feb 2021, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2016
First posted
Aug 17, 2016
StartActual
Jul 29, 2016
Primary completionActual
Mar 15, 2017
CompletionActual
Mar 15, 2017
Results first posted
Feb 18, 2021
Last update
Oct 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02870309
Collaborators
Grifols Japan K.K.
Responsible party
Sponsor
First posted
Aug 17, 2016
Start date
Jul 29, 2016
Primary completion
Mar 15, 2017
Completion
Mar 15, 2017
Results posted
Feb 18, 2021
Last update
Oct 28, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion